Cardiorenal Syndrome
Definition
Cardiorenal syndrome (CRS) refers to the bidirectional pathophysiological interaction between the heart and kidneys, whereby dysfunction of one organ induces or perpetuates dysfunction in the other. In advanced heart failure, kidney dysfunction encompasses not only reduced eGFR but also inadequate maintenance of sodium and volume homeostasis, retention of uremic solutes, and disrupted endocrine functions. More than two-thirds of patients with advanced HF have some degree of kidney dysfunction, driven by shared comorbidities, hemodynamic insults, neurohormonal dysregulation, and systemic biological derangements.
Key Concepts
Assessment of Kidney Function in Advanced HF
- Standard eGFR via serum creatinine is unreliable in advanced HF: sarcopenia (very common in advanced HF) causes low creatinine, underestimating kidney dysfunction; cystatin C preferred in low-muscle-mass patients (sources/AKI-HF-AHA-2024, rating: very high)
- Serum creatinine (not eGFR) preferred for day-to-day tracking during hospitalisations for acute decompensated HF (sources/AKI-HF-AHA-2024, rating: very high)
- Multi-domain assessment recommended: glomerular function, tubular function, endocrine function (erythropoietin, RAAS), solute/volume homeostasis, and reversibility potential (sources/AKI-HF-AHA-2024, rating: very high)
- Urinary biomarkers of tubular injury (KIM-1, NGAL, NAG) may be discordant with serum creatinine changes in acute HF — a creatinine rise during decongestion does not necessarily reflect tubular injury (sources/AKI-HF-AHA-2024, rating: very high)
Reversibility Assessment
- Staged reversibility assessment: alleviate contributing hemodynamic factors (venous congestion, kidney hypoperfusion, intra-abdominal hypertension) → quantify kidney response across multiple domains (sources/AKI-HF-AHA-2024, rating: very high)
- Transkidney perfusion pressure (TKPP) = MAP − CVP; goal >60 mmHg to optimise single-nephron filtration kinetics (sources/AKI-HF-AHA-2024, rating: very high)
- Creatinine rise >1.5× baseline or >50% eGFR drop (especially with rising NT-proBNP or elevated lactate) → high-risk population; consider pulmonary artery catheter-guided hemodynamic evaluation (sources/AKI-HF-AHA-2024, rating: very high)
- Venous congestion may have a larger (but more reversible) impact on eGFR decline than reduced cardiac output; kidney venous flow ultrasound may help characterise this (not yet standard of care) (sources/AKI-HF-AHA-2024, rating: very high)
Irreversible Intrinsic Kidney Disease
- Markers suggesting irreversibility: microscopic hematuria, acanthocytes, cellular casts on urinalysis; proteinuria/albuminuria; echogenic kidneys with cortical thinning or reduced kidney size on ultrasound; biopsy showing nephron fibrosis/atrophy (sources/AKI-HF-AHA-2024, rating: very high)
- Intrinsic kidney disease = loss of nephron mass or individual nephron dysfunction in tubule, glomerulus, interstitium, or vasculature — generally not reversible after hemodynamic optimisation (sources/AKI-HF-AHA-2024, rating: very high)
- If eGFR decline persists despite substantial improvements in cardiac output, decongestion, and MAP, further improvement is unlikely — may predict kidney injury with advanced surgical treatments (sources/AKI-HF-AHA-2024, rating: very high)
Neurohormonal Mechanisms
- RAAS upregulation, sympathetic activation, and arginine vasopressin stimulation all drive sodium/water retention and eGFR decline in advanced HF (sources/AKI-HF-AHA-2024, rating: very high)
- AVP stimulates urea nitrogen reabsorption → elevated BUN:creatinine ratio; independently predicts higher mortality (sources/AKI-HF-AHA-2024, rating: very high)
- Hyponatremia: Reflects salt-and-water avid state; independently associated with mortality in HF (sources/AKI-HF-AHA-2024, rating: very high)
- Hypochloremia: Reduced chloride delivery to macula densa → juxtaglomerular renin release → worsened sodium retention downstream; independently predicts mortality in acute decompensated HF (sources/AKI-HF-AHA-2024, rating: very high)
- Urinary sodium <50–70 mEq/L after loop diuretics = heightened kidney sodium avidity; poor prognostic marker (sources/AKI-HF-AHA-2024, rating: very high)
GDMT and Kidney Function — Paradox of eGFR Decline
- Pharmacological eGFR decline with RAAS inhibitors or SGLT2 inhibitors is paradoxically renoprotective: acute intraglomerular pressure reduction attenuates long-term functional nephron loss (sources/AKI-HF-AHA-2024, rating: very high)
- Do NOT discontinue GDMT (including loop diuretics in congested patients) solely for eGFR decline — de-escalating diuretics to preserve eGFR can lead to worsening congestion and adverse outcomes (sources/AKI-HF-AHA-2024, rating: very high)
- Initial SGLT2i eGFR dip paradoxically associated with improved cardiovascular outcomes and reduced major kidney events (DAPA-HF, EMPA-KIDNEY) (sources/AKI-HF-AHA-2024, rating: very high)
Heart-Kidney (H-K) Profiles
- Proposed clinical classification based on kidney function trajectory, hemodynamics, and treatment response (sources/AKI-HF-AHA-2024, rating: very high):
- Profile A: No kidney dysfunction
- Profile B: Transient HF-related kidney dysfunction — reversible with hemodynamic and medical optimisation (GDMT ± temporary MCS)
- Profile C: Persistent kidney dysfunction despite vasoactive drugs or temporary MCS — requires KRT
- Profile B → identify patients with reversible dysfunction who benefit from optimisation before advanced therapy
- Profile C → identify patients requiring KRT planning; necessitate sHKTx consideration if proceeding to transplantation
Kidney Dysfunction and LVAD
- Preoperative kidney dysfunction (especially if requiring KRT) is a strong predictor of poor LVAD outcomes: high perioperative/postoperative mortality, thrombosis, bleeding, and infections (sources/AKI-HF-AHA-2024, rating: very high)
- Chronic KRT before LVAD implantation: median post-implantation survival ~3 weeks (sources/AKI-HF-AHA-2024, rating: very high)
- Pre-LVAD: temporary MCS/inotropes/vasodilators to test kidney reversibility is reasonable (no validated protocol) (sources/AKI-HF-AHA-2024, rating: very high)
- Post-LVAD AKI: 37% (meta-analysis n>63,000); 13% require KRT; early eGFR improvement in 85% but sustained improvement in only 3.3% (sources/AKI-HF-AHA-2024, rating: very high)
- RV failure post-LVAD worsens kidney outcomes by causing persistent venous congestion — target CVP <10–12 mmHg (sources/AKI-HF-AHA-2024, rating: very high)
Kidney Dysfunction and Heart Transplantation
- sHKTx evaluation: all HTx candidates with eGFR <45 mL/min/1.73m²; UNOS eligibility criterion: eGFR ≤30 mL/min/1.73m² (sources/AKI-HF-AHA-2024, rating: very high)
- eGFR <30 or KRT-dependent: retrospective data support sHKTx over HTx alone for survival (sources/AKI-HF-AHA-2024, rating: very high)
- Post-HTx kidney failure requiring dialysis: 13.4% within 90 days; independent predictors include ECMO, IABP, ventilator use, longer ischemia time (sources/AKI-HF-AHA-2024, rating: very high)
- Delayed kidney graft function in sHKTx: 27–37%; primary kidney nonfunction: 14–33% (sources/AKI-HF-AHA-2024, rating: very high)
- Safety net policy: priority access to deceased donor kidneys for HTx recipients meeting KTx criteria at 60–365 days post-HTx (sources/AKI-HF-AHA-2024, rating: very high)
Dialysis Modalities in Advanced HF
- Hemodialysis: High ultrafiltration rates cause hemodynamic instability (especially 3–4×/week); platelet dysfunction + endothelial dysfunction → paradoxical bleeding + prothrombotic state; central catheter infection risk; logistically complex for LVAD patients (sources/AKI-HF-AHA-2024, rating: very high)
- Peritoneal dialysis: Preferred for LVAD patients and medically managed advanced HF patients — smaller hemodynamic shifts, no vascular access, no heparin, home-based, preserves residual kidney function; current-generation intrapericardial LVAD placement reduces peritonitis/infection risk (sources/AKI-HF-AHA-2024, rating: very high)
Contradictions / Open Questions
- No validated pre-LVAD kidney optimization protocol: Significant inter-centre variability in tolerance of preoperative kidney dysfunction for LVAD implantation; it is also possible that kidney function may worsen after MCS in some patients (sources/AKI-HF-AHA-2024, rating: very high)
- Kidney Failure Risk Equation not validated in advanced HF: Standard CKD prediction tools may not apply; future validated tools needed (sources/AKI-HF-AHA-2024, rating: very high)
- Serum creatinine rise during decongestion ≠ tubular injury: Studies show worsening renal function during aggressive diuresis is NOT associated with tubular injury markers (KIM-1, NGAL), yet clinicians often interpret creatinine rise as a reason to reduce diuresis — this can worsen congestion and outcomes (sources/AKI-HF-AHA-2024, rating: very high)
- sHKTx evidence is retrospective: No RCT data for sHKTx vs. HTx alone; decision-making relies on registry data and single-centre series (sources/AKI-HF-AHA-2024, rating: very high)
CRS Classification (Acute Dialysis Quality Initiative 5-Type System)
(sources/cardiorenal-aha-2019, rating: very high)
- Type 1 (Acute CRS): Acute HF (e.g., ACS with cardiogenic shock) → AKI; affects up to 40% of patients hospitalised for AHF
- Type 2 (Chronic CRS): Chronic HF → CKD; 16% of Type 2 CRS patients develop acute CRS
- Type 3 (Acute Renocardiac): AKI (volume overload, inflammatory surge, uremic metabolic disturbance) → AHF
- Type 4 (Chronic Renocardiac / Uremic Cardiomyopathy): CKD → chronic HF; LVH driven by CKD-associated cardiomyopathy; FGF-23 has an independent causal effect on LV hypertrophy; 20% of Type 4 CRS develop acute CRS
- Type 5 (Secondary CRS): Systemic disease (amyloidosis, sepsis, cirrhosis) → simultaneous HF and kidney failure
Hemodynamic Pathophysiology: CVP, Not Just Low CO
(sources/cardiorenal-aha-2019, rating: very high)
- Elevated CVP → renal venous hypertension → increased renal resistance → impaired intrarenal blood flow → decreased GFR — primary driver, not reduced cardiac output alone
- ADHERE registry: rising serum creatinine was similar in AHF patients with reduced vs preserved systolic function; many acute CRS patients have preserved or elevated BP
- ESCAPE trial post hoc: RA pressure was the only hemodynamic parameter associated with baseline renal dysfunction
- Elevated IAP (in 60% of AHF admissions) contributes to renal dysfunction via direct renal compression; decongestive therapy reversal ameliorates creatinine
- RV dysfunction contributes to CRS through ventricular interdependence, paradoxical septal movement, and reduced LV filling
- Non-hemodynamic mechanisms: RAAS/SNS activation, FGF-23 (LVH), proinflammatory endothelial phenotype from venous congestion, TNFα/IL-1/IL-6 cardiodepressant effects
Biomarkers in CRS
(sources/cardiorenal-aha-2019, rating: very high)
- NGAL: Most upregulated protein in AKI; meta-analysis (n=2000): pooled AUC 0.78/0.75 for dialysis/death; serial NGAL improves prediction (AUC 0.91)
- TIMP-2 × IGFBP7: G1 cell cycle arrest markers; superior to other AKI biomarkers in SAPPHIRE validation (n=728); commercially available in the US
- Cystatin C: Highest quartile (>1.55 mg/L) → 2× CV mortality; strong predictor of rehospitalisation and mortality in AHF; additive with NT-proBNP and troponin T
- BNP levels in CKD: Higher at baseline due to impaired renal clearance AND chronic pressure/volume overload; significantly elevated in CRS vs AHF without renal impairment
- ST2: Not affected by renal function — useful in CKD patients where natriuretic peptides are confounded
- Galectin-3: Worse renal function associated with higher levels; independently predicts all-cause mortality; 15% increase over 3–6 months predicts mortality/HHF
Ultrafiltration in CRS
(sources/cardiorenal-aha-2019, rating: very high)
- UNLOAD (n=200, AHF): UF vs diuretics — greater weight loss (5.0 vs 3.1 kg, P=0.001); no dyspnoea difference; reduced 90-day rehospitalisation. Diuretic arm may have been underdosed
- CARRESS-HF (n=188, Type 1 CRS specifically): Fixed-rate UF vs stepwise diuretic algorithm — no difference in weight loss; fixed-rate UF significantly worsened creatinine (+0.23 vs −0.04 mg/dL, P=0.003); higher adverse events (72% vs 53%). Strong argument against primary UF in Type 1 CRS
- AVOID-HF: Terminated early; nonsignificant trend toward fewer HF readmissions; higher adverse events in UF arm
- Fixed-rate UF protocols physiologically conflict with documented decreases in plasma refill rates during continuous ultrafiltration
Diuretic Strategies in CRS
(sources/cardiorenal-aha-2019, rating: very high)
- High-dose intermittent furosemide is safe and effective in AHF (DOSE-AHF, pooled CARRESS-HF/ROSE-AHF analysis)
- Stepwise diuretic algorithm targeting 3–4 L urine/24h with furosemide ± metolazone: greater fluid removal and improved renal function vs standard care
- Do NOT interpret creatinine rise during aggressive diuresis as true AKI — tubular injury markers (NGAL, KIM-1, NAG) are not elevated with diuresis-related creatinine rise; paradoxically associated with improved survival in ROSE-AHF
- See concepts/Diuretic-Resistance for mechanisms of resistance and strategies
RAAS Inhibition Across CKD Spectrum
(sources/cardiorenal-aha-2019, rating: very high)
- ACEi/ARB: mortality benefits preserved across CKD subgroups in post hoc analyses (SOLVD, DIG, CONSENSUS); evidence in advanced CKD (stages 4–5) limited
- Sacubitril/valsartan (PARADIGM-HF subset): slower GFR decline vs enalapril; PARAMOUNT: preserves eGFR better in HFpEF (−1.6 vs −5.2 mL/min/1.73m²)
- MRA: RALES and EMPHASIS-HF benefits preserved across CKD subgroups; hyperkalemia risk doubled; novel antihyperkalemic agents (patiromer, sodium zirconium cyclosilicate) may enable continued use
Contradictions / Open Questions
- No validated pre-LVAD kidney optimization protocol: Significant inter-centre variability in tolerance of preoperative kidney dysfunction for LVAD implantation; it is also possible that kidney function may worsen after MCS in some patients (sources/AKI-HF-AHA-2024, rating: very high)
- Kidney Failure Risk Equation not validated in advanced HF: Standard CKD prediction tools may not apply; future validated tools needed (sources/AKI-HF-AHA-2024, rating: very high)
- Serum creatinine rise during decongestion ≠ tubular injury: Studies show worsening renal function during aggressive diuresis is NOT associated with tubular injury markers (KIM-1, NGAL), yet clinicians often interpret creatinine rise as a reason to reduce diuresis — this can worsen congestion and outcomes (sources/AKI-HF-AHA-2024, rating: very high; sources/cardiorenal-aha-2019, rating: very high)
- sHKTx evidence is retrospective: No RCT data for sHKTx vs. HTx alone; decision-making relies on registry data and single-centre series (sources/AKI-HF-AHA-2024, rating: very high)
- UF vs diuretics in Type 1 CRS: CARRESS-HF showed harm with fixed-rate UF; UNLOAD showed benefit without AKI selection. Optimal patient selection and protocol for ultrafiltration in CRS remains undefined (sources/cardiorenal-aha-2019, rating: very high)
- Evidence gap in CKD stages 4–5: Most HF trials excluded Cr >2.5 mg/dL; ICD/CRT data in advanced CKD relies on post hoc subgroup analyses; beta-blocker discontinuation rates were higher in the lowest eGFR subgroups (sources/cardiorenal-aha-2019, rating: very high)
Connections
- Related to entities/Heart-Failure
- Related to concepts/HFpEF
- Related to concepts/Right-Heart-Catheterization — hemodynamic assessment is central to reversibility evaluation
- Related to concepts/Diuretic-Resistance — mechanisms and management of diuretic resistance in CRS
- Related to sources/AKI-HF-AHA-2024
- Related to sources/cardiorenal-aha-2019